Compare CAAS & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CAAS | KRRO |
|---|---|---|
| Founded | N/A | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.8M | 150.0M |
| IPO Year | 2025 | 2019 |
| Metric | CAAS | KRRO |
|---|---|---|
| Price | $4.44 | $12.84 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $34.80 |
| AVG Volume (30 Days) | 25.7K | ★ 154.2K |
| Earning Date | 04-22-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,392,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.97 | ★ N/A |
| Revenue Growth | N/A | ★ 181.46 |
| 52 Week Low | $3.80 | $5.20 |
| 52 Week High | $5.15 | $55.89 |
| Indicator | CAAS | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 57.59 | 49.25 |
| Support Level | $4.12 | $12.51 |
| Resistance Level | $4.61 | $14.76 |
| Average True Range (ATR) | 0.12 | 0.76 |
| MACD | 0.03 | -0.16 |
| Stochastic Oscillator | 65.85 | 16.63 |
China Automotive Systems Inc is a holding company. The firm through its subsidiary is a supplier of power steering systems and components to China's automotive industry. Its product offering encompasses a full range of auto parts incorporated into steering systems for both passenger automobiles and commercial vehicles. The company offers four separate series, models of power steering including rack and pinion power steering, integral power steering, electronic power steering and manual steering, steering columns, steering oil pumps, and steering hoses. Geographically, it derives a majority of its revenue from China.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.